Assembly Bill A705B

2021-2022 Legislative Session

Relates to the availability of buprenorphine in opioid treatment programs

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Assembly Committee

  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

Bill Amendments

2021-A705 - Details

See Senate Version of this Bill:
S6746
Current Committee:
Assembly Ways And Means
Law Section:
Mental Hygiene Law
Laws Affected:
Add §32.12, Ment Hyg L
Versions Introduced in Other Legislative Sessions:
2019-2020: A5953
2023-2024: A1055, S3347

2021-A705 - Summary

Requires facilities that provide treatment for substance use disorders to have at least one practitioner qualified to administer or prescribe buprenorphine to individuals in their care with substance use disorders related to opioids.

2021-A705 - Bill Text download pdf 

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                    705
 
                        2021-2022 Regular Sessions
 
                           I N  A S S E M B L Y
 
                                (PREFILED)
 
                              January 6, 2021
                                ___________
 
 Introduced  by  M.  of  A. L. ROSENTHAL -- read once and referred to the
   Committee on Alcoholism and Drug Abuse
 
 AN ACT to amend the mental hygiene law, in relation to the  availability
   of buprenorphine in opioid treatment programs

   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. The mental hygiene law is amended by adding a  new  section
 32.12 to read as follows:
 § 32.12 AVAILABILITY OF BUPRENORPHINE.
   ANY  PROVIDER  OF  SERVICES  OR FACILITY PROVIDING CHEMICAL DEPENDENCE
 SERVICES SHALL  HAVE  BUPRENORPHINE  AVAILABLE  TO  BE  ADMINISTERED  TO
 ADDICTS.  SUCH CONTROLLED SUBSTANCE SHALL BE ADMINISTERED BY A PHYSICIAN
 OR GROUP OF PHYSICIANS PURSUANT TO SUBDIVISION (B) OF SECTION  32.05  OF
 THIS ARTICLE.
   § 2. This act shall take effect on the one hundred twentieth day after
 it shall have become a law.  Effective immediately, the addition, amend-
 ment and/or repeal of any rule or regulation necessary for the implemen-
 tation  of  this act on its effective date are authorized to be made and
 completed on or before such effective date.
 
 
 
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD00547-01-1

2021-A705A - Details

See Senate Version of this Bill:
S6746
Current Committee:
Assembly Ways And Means
Law Section:
Mental Hygiene Law
Laws Affected:
Add §32.12, Ment Hyg L
Versions Introduced in Other Legislative Sessions:
2019-2020: A5953
2023-2024: A1055, S3347

2021-A705A - Summary

Requires facilities that provide treatment for substance use disorders to have at least one practitioner qualified to administer or prescribe buprenorphine to individuals in their care with substance use disorders related to opioids.

2021-A705A - Bill Text download pdf 

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  705--A
 
                        2021-2022 Regular Sessions
 
                           I N  A S S E M B L Y
 
                                (PREFILED)
 
                              January 6, 2021
                                ___________
 
 Introduced  by  M.  of  A. L. ROSENTHAL -- read once and referred to the
   Committee on Alcoholism and Drug Abuse -- committee  discharged,  bill
   amended,  ordered reprinted as amended and recommitted to said commit-
   tee
 
 AN ACT to amend the mental hygiene law, in relation to the  availability
   of buprenorphine in opioid treatment programs
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. The mental hygiene law is amended by adding a  new  section
 32.12 to read as follows:
 § 32.12 AVAILABILITY OF BUPRENORPHINE.
   EVERY   FACILITY  LICENSED  OR  AUTHORIZED  TO  PROVIDE  SERVICES  FOR
 SUBSTANCE USE DISORDERS RELATED TO  OPIOIDS  THAT  EMPLOYS  A  QUALIFIED
 PRACTITIONER,  AS  DETERMINED  BY FEDERAL LAW, SHALL ENSURE AT LEAST ONE
 PRACTITIONER IN THE FACILITY HAS RECEIVED AN APPROPRIATE  WAIVER  AND/OR
 HAS  COMPLETED REQUIRED TRAINING TO ADMINISTER BUPRENORPHINE TO INDIVID-
 UALS IN THEIR CARE WITH A SUBSTANCE USE  DISORDER  WHERE  SUCH  DRUG  IS
 DETERMINED APPROPRIATE FOR THEIR TREATMENT.
   § 2. This act shall take effect on the one hundred twentieth day after
 it shall have become a law.  Effective immediately, the addition, amend-
 ment and/or repeal of any rule or regulation necessary for the implemen-
 tation  of  this act on its effective date are authorized to be made and
 completed on or before such effective date.
 
 
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD00547-03-1

2021-A705B (ACTIVE) - Details

See Senate Version of this Bill:
S6746
Current Committee:
Assembly Ways And Means
Law Section:
Mental Hygiene Law
Laws Affected:
Add §32.12, Ment Hyg L
Versions Introduced in Other Legislative Sessions:
2019-2020: A5953
2023-2024: A1055, S3347

2021-A705B (ACTIVE) - Summary

Requires facilities that provide treatment for substance use disorders to have at least one practitioner qualified to administer or prescribe buprenorphine to individuals in their care with substance use disorders related to opioids.

2021-A705B (ACTIVE) - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  705--B
 
                        2021-2022 Regular Sessions
 
                           I N  A S S E M B L Y
 
                                (PREFILED)
 
                              January 6, 2021
                                ___________
 
 Introduced  by  M.  of  A. L. ROSENTHAL -- read once and referred to the
   Committee on Alcoholism and Drug Abuse -- committee  discharged,  bill
   amended,  ordered reprinted as amended and recommitted to said commit-
   tee -- reported and referred to the Committee on  Ways  and  Means  --
   recommitted  to  the  Committee  on  Ways and Means in accordance with
   Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered
   reprinted as amended and recommitted to said committee
 
 AN ACT to amend the mental hygiene law, in relation to the  availability
   of buprenorphine in opioid treatment programs
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. The mental hygiene law is amended by adding a  new  section
 32.12 to read as follows:
 § 32.12 AVAILABILITY OF BUPRENORPHINE.
   EVERY   FACILITY  LICENSED  OR  AUTHORIZED  TO  PROVIDE  SERVICES  FOR
 SUBSTANCE USE DISORDERS RELATED TO  OPIOIDS  THAT  EMPLOYS  A  QUALIFIED
 PRACTITIONER,  AS  DETERMINED  BY FEDERAL LAW, SHALL ENSURE AT LEAST ONE
 PRACTITIONER IN THE FACILITY HAS RECEIVED AN APPROPRIATE  WAIVER  AND/OR
 HAS COMPLETED REQUIRED TRAINING TO ADMINISTER OR PRESCRIBE BUPRENORPHINE
 TO  INDIVIDUALS  IN  THEIR CARE WITH A SUBSTANCE USE DISORDER WHERE SUCH
 DRUG IS DETERMINED APPROPRIATE FOR THEIR TREATMENT.
   § 2. This act shall take effect on the one hundred twentieth day after
 it shall have become a law.  Effective immediately, the addition, amend-
 ment and/or repeal of any rule or regulation necessary for the implemen-
 tation of this act on its effective date are authorized to be  made  and
 completed on or before such effective date.
 
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD00547-06-2

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.